Pharma

Your Article Summary

See Latest Articles

FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec
Bristol Myers-Squibb Company, 05/27/09

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has granted full approval for SPRYCEL for the treatment of adults in all phases of chronic myeloid leukemia with resistance or intolerance to prior therapy including Gleevec (imatinib mesylate).

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09

 See all of Drug/Product Approvals